Are you "Profiting from the Pros?"
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.
If you wish to go to ZacksTrade, click
OK. If you do not, click Cancel.
Back to top
Hospira Inc. soared to a 52-week high of $39.48 towards the end of the trading session on Jul 9, 2013 buoyed by the positive opinion issued by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) regarding the approval of Inflectra (infliximab).
The closing price of this company on that day was $39.44, representing an impressive year-to-date return of 24.1%. Moreover, Perrigo has delivered positive earnings surprises in each of the last four quarters with an average beat of 7.14%. The long-term expected earnings growth rate for this stock is 7.9%. Favorable CHMP Opinion- A big Positive
Shares of Hospira have been on the upswing ever since the CHMP recommended the approval of Inflectra for the treatment of rheumatoid arthritis, inflammatory bowel disease and plaque psoriasis. We note that Inflectra is the biosimilar version of Johnson & Johnson / Merck & Co. Inc’s ( JNJ - Analyst Report) /( MRK - Analyst Report) blockbuster drug Remicade. Hospira noted in its press release that Inflectra is the first monoclonal antibody therapy to receive a favorable opinion from the CHMP after review through the EMA biosimilars regulatory pathway.
Hospira, which currently markets two biosimilars in Europe, boasts of a strong biosimilars pipeline with 11 candidates in development. Biosimilars, which are generic versions of biologic drugs, are expected to be a significant growth driver in the generics industry in the coming years. The biosimilars market represents huge commercial opportunity with a significant amount of biologic sales slated to lose patent protection in the coming years. A Stock Worth Considering
Hospira carries a Zacks Rank #3 (Hold). One can consider ResMed Inc. ( RMD - Analyst Report) a good buying opportunity. This medical stock – sporting a Zacks Rank #2 (Buy) – has performed encouragingly over the last few quarters with potential to rise significantly from current levels.